IN Brief:
- The Zhenjiang Dagang plant produces glass vials and ampoules for injectable medicines.
- Automated production and logistics connect material flow with controlled cleanroom operations.
- A further 33,000m² remains available for future development at the site.
Gerresheimer has begun operations at a 40,000m² pharmaceutical-packaging plant in Zhenjiang Dagang, Jiangsu Province, doubling its Chinese production capacity for primary glass packaging used with injectable medicines.
The facility manufactures pharmaceutical vials and ampoules, with most output destined for customers in China. Developed through Gerresheimer’s joint venture with Shuangfeng Glass, it becomes the company’s fourth tubular-glass plant in the country and provides room for further expansion on an adjoining 33,000m² plot.
Approximately 250 people are working at the site, with around 50 additional positions expected as production increases. Automated glass-forming and logistics equipment connect manufacturing with internal material movement, while controlled areas support coating, microbiological testing, inspection, and preparation.
More than 2,700m² of ISO Class 8 cleanroom space has been installed, alongside an ISO Class 7 microbiological laboratory and over 700m² devoted to silicone coating under ISO Class 8 conditions. Those environments allow containers to move through defined processes while limiting contamination and maintaining the evidence required for regulated pharmaceutical supply.
Glass vials and ampoules occupy a small physical part of the finished medicine, yet their performance is inseparable from the product they contain. Dimensional consistency, surface quality, break resistance, particulate control, coating, and compatibility with filling equipment all influence whether a container can be used at commercial scale.
Substitution is consequently more complex than changing an ordinary packaging format. Pharmaceutical manufacturers qualify materials, dimensions, suppliers, coatings, production processes, and container behaviour as part of the finished product’s specification. Moving to a different source may require testing, documentation, regulatory work, and production-line adjustment before supply can resume.
The Jiangsu plant therefore adds regional resilience as well as nominal output. Chinese pharmaceutical manufacturers gain more local capacity for components that can become difficult to replace during disruption, while Gerresheimer can support customers without relying entirely on longer international movements between glass production, filling operations, and final distribution.
Automated internal logistics should reduce uncontrolled handling and strengthen the link between material identity, quality status, and physical location. Semi-finished containers, packaging materials, quarantined stock, released batches, and rejected goods need separate statuses, even when they occupy neighbouring storage positions within the same building.
That relationship between regulated production and automated storage is already visible elsewhere in Gerresheimer’s network. At its medical-device operation in Georgia, two automated warehouse systems now connect moulding, component storage, inventory control, and downstream production, reducing manual transfer between controlled processes.
Quality capacity must expand alongside manufacturing because finished goods cannot enter the customer supply chain until testing and documentation are complete. Additional forming lines may increase physical output, but a shortage of inspection, laboratory, release, or controlled-storage capacity can leave growing volumes waiting inside the plant.
The new microbiological laboratory gives those activities a direct position within the Zhenjiang operation. Bringing testing closer to production can shorten internal movements and improve coordination, although laboratory throughput, sampling plans, data integrity, and release procedures must keep pace with the larger manufacturing base.
Automation also concentrates dependence on equipment and systems. Glass-forming lines, cleanroom controls, inspection machinery, conveyors, and warehouse software must operate as a connected process, and an interruption at one stage may restrict output elsewhere. Maintenance planning and critical-spares availability become central to supply continuity once manual alternatives have been reduced.
Gerresheimer has incorporated a 2MWp rooftop solar installation, rainwater and air-conditioning condensate recovery, and waste-heat utilisation into the site. The plant has been designed around China’s Green Factory programme and LEED Gold certification requirements, addressing some of the energy and resource demand created by glass production, cleanrooms, ventilation, and automated handling.
Utility resilience remains closely tied to operational capacity. High-temperature forming, controlled environments, laboratory systems, and automated equipment require stable electricity, cooling, compressed air, and environmental controls, making the plant’s energy infrastructure part of the pharmaceutical supply chain rather than a separate property consideration.
With 39 production sites across Europe, the Americas, and Asia, Gerresheimer has been increasing regional capacity for products whose qualification cycles limit rapid sourcing changes. The available expansion land at Zhenjiang gives the company a route to add production, technical services, or storage as customer programmes progress without establishing another distant operation.
Demand for injectable medicines can rise more quickly than qualified packaging capacity, particularly when a new therapy, public-health programme, or regional manufacturing investment moves into commercial production. By combining additional glass output with controlled logistics and testing, the Jiangsu plant strengthens the less visible industrial base on which those medicines depend.
